ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 048

Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study

Orly Ohana1, Itay Marmor2, Liora Harel3, Shiri Rubin4, rotem tal5, Yoel Levinsky6, Orit Peled7 and Gil Amarilyo3, 1Pediatric C ward, Schneider Children's Medical Centre, Petach Tikva, Israel, 2Dana-Dwek Children's Hospital, Hod Hasharon, Israel, 3Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, 4Pediatric Ear Nose and Throat Unit Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 5Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 6Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, 7Department of Pharmacy, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Ibuprofen, Juvenile idiopathic arthritis, naproxen, Nonsteroidal antiinflammatory drugs (NSAIDs)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, March 30, 2023

Title: Posters: Clinical and Therapeutic I

Session Type: Poster Session A

Session Time: 6:00PM-7:00PM

Background/Purpose: JIA is the most common childhood rheumatic disease. NSAIDs and intraarticular corticosteroid injections (IACI) are first-line therapy for oJIA. NSAIDs Adverse events (AEs) include gastrointestinal ulcers/bleeding and impaired renal function.

The most prescribed NSAIDs for oJIA are ibuprofen (IBU) and naproxen (NAP). However, direct comparison between these drugs is lacking. We aimed to compare the efficacy and safety of IBU vs. NAP for oJIA.

Methods: This is bi-national retrospective study of oJIA patients from Schneider Childrens Medical Center (SCMCI) and in St. Louis Children’s Hospital (STL) treated with either IBU or NAP as first-line therapy. Efficacy was defined as patients that achieved complete response (CR=no evidence for arthritis). Safety was assessed by the occurrence of AEs during follow-up.

Results: Of 171 patients, 104 were treated in SCMCI and 67 in STL. The study population had a mean age of 4.48 years, with female/male ratio ~2.5:1 (71.9% vs. 28.1%). 110 patients (64%) were treated with NAP and 61 (36%) with IBU. No significant difference was found in drug efficacy [CR 10/61 (16.4%) IBU vs. 19/110 (17.3%) NAP (P=0.83)]. Treatment duration 28 days was associated with significantly higher odds for CR (p=0.017). For safety, 13 AEs were associated with NAP, whereas only one for IBU (p=0.02). Treatment was discontinued in all AEs cases.

Conclusion: IBU and NAP showed similar albeit low efficacy which emphasizes their role as bridging therapy until IACI is achieved. However, IBU showed better safety profile NAP and therefore should be considered as first-line therapy.


Disclosures: O. Ohana: None; I. Marmor: None; L. Harel: None; S. Rubin: None; r. tal: None; Y. Levinsky: None; O. Peled: None; G. Amarilyo: None.

To cite this abstract in AMA style:

Ohana O, Marmor I, Harel L, Rubin S, tal r, Levinsky Y, Peled O, Amarilyo G. Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/comparative-efficacy-and-safety-of-ibuprofen-and-naproxen-in-the-treatment-of-oligoarticular-juvenile-idiopathic-arthritis-ojia-bi-national-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-efficacy-and-safety-of-ibuprofen-and-naproxen-in-the-treatment-of-oligoarticular-juvenile-idiopathic-arthritis-ojia-bi-national-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology